^
Association details:
| Biomarker: | MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Use of Cabozantinib to Treat MET -amplified Pediatric Colorectal Cancer
Published date:
05/03/2022
Excerpt:
Here, a 13-year-old male with advanced CRC underwent cancer gene panel testing, which detected 4 genetic abnormalities ( MET amplification in addition to TP53 , SMAD4 , and CTNNA1 mutations) that might be associated with a poor prognosis. Based on high-level MET amplification, he received a multikinase inhibitor, cabozantinib, after failure of first-line and second-line chemotherapy, resulting in transient disease stabilization.
DOI:
10.1097/MPH.0000000000002482
